SCAPHO 150MG Injection
DESCRIPTION
Secukinumab belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful jointsScapho 150mg is a prescription drugs which is used under proper guidance of medical oncologist
Scapho 150mg injection |
INDICATION
Scapho 150mg indicated for the treatment of following conditionPlaque Psoriasis
Psoriatic arthritis
Ankylosing spondylitis.
DOSAGE
Plaque Psoriasis:Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
For some patientsmay be acceptable containing dose of Scapho 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Recommended dosage
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho 150mg injection with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho 150mg without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Ankylosing Spondylitis:
Given with or without a loading dosage by SC injection
Scapho 150mg with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho 150mg injection without a loading dose is administrated150 mg SC q4wk
MECHANISM
Secukinumab mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and is found in peak concentrations in psoriasis plaques.Secukinumab consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.
ADME
Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 daysVolume of distribution is 7.1 – 8.6 (IV administration)
The drug scapho is Metabolized via intracellular catabolism.
Scapho 150mg has half-life is 22-31 days
PRECAUTION
Scapho 150mg injection may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infectionBefore to initiation of Scapho 150mg, start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
May infuriate Crohn disease
Anaphylaxis and cases of urticaria resulted; if this appears, discontinue Scapho 150mg injection immediately and start anaphylaxis treatment
DRUG INTERACTION
Live vaccinations combination with Scapho 150mg should be avoidedCYP450 substrates concomitant use with Scapho 150mg injection may altered by increased levels of certain cytokines.
CONTRAINDICATION
Patients having Serious hypersensitivity reactions to the active substance or to any of the excipientsSTORAGE
Store the drug at 2℃ to 8℃.MISSED DOSE
In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.thereby missed dose should be avoid and follow the regular dosing schedule.
SIDE EFFECTS
• Infections• Nasopharyngitis
• Diarrhea
• URT infection
• Rhinitis
• Oral herpes
• Pharyngitis
• Urticaria
• Rhinorrhoea
Address:
Apartment No.304 A Wing,Shiva Sakthi chs lts,
JP Road, Near Apna Bazar,
Andheri(West),
Mumbai - 400058
Maharashtra.
Comments
Post a Comment